In a large real-world Italian cohort, GLP-1 receptor agonist therapy led to measurable rates of type 2 diabetes remission, ...

Initial Clinical Data Expected in the First Half of 2026SAN CARLOS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a ...

A 67-year-old man presented with multiorgan failure, hypoglycaemia, cholestatic liver dysfunction, and two duodenal ulcers ...

Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium-- HAMPTON, N.J., Oct. 30, 2025 (GLOBE ...

Eli Lilly and Company and Walmart Inc. announced a collaboration to expand access to direct-to-consumer pricing for Zepbound (tirzepatide) single-dose vials available through LillyDirect. Zepbound ...

This article was reviewed by Lynn Marie Morski, MD, JD. How Long Does Ozempic® Stay in Your System? Key takeaways: Ozempic® ...

Altimmune continues developing pemvidutide for MASH but has yet to secure a partner or acquisition despite sector M&A ...

A new oral medication, Orforglipron, is set to revolutionize weight loss and diabetes management, offering a pill alternative ...

This press release corrects and replaces the company’s press release issued today, 10/29, at 4:15 p.m. ET in order to correct a typographical ...

A RECENT Greek study presented at EASD 2025 has suggested that semaglutide, a glucagon-like peptide-1 (GLP-1) receptor ...

Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is ...

Rybelsus is now FDA-approved for managing cardiovascular health. Doctors say oral GLP-1s may reduce heart attack and stroke ...